Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by Charly50on Dec 29, 2021 9:04am
326 Views
Post# 34266972

RE:RE:RE:RE:RE:RE:RE:Catching breath

RE:RE:RE:RE:RE:RE:RE:Catching breath
Rix, that is how it is.
There are always 2 sides to the coin.
Because so many expect it, it will happen.
 
Mustang has called the catalysts:
 
Licensing Deals
 
-Dr. Piotr Witkowski, the study leader, will confirm on January 13, 2022, at the Winter Symposium, that 3 patients have been insulin free for 12+ months and 2 patients have been insulin free for 6+ months.
 
-Note also the date : JP MORGAN HEALTHCARE CONFERENCE 2022.
JANUARY 10-14, 2022.
 
-New analysis Canaccard (old 2.50).
 
-chart breakout at 1.70
(typical also here on the 24th again the setback uf this line, before we then closed at 1.90.
 
 in January 21, the highest price in the course of the day was 2.87
 
It is much too early to sell.
 
GL to all.
<< Previous
Bullboard Posts
Next >>